Neuroblastoma

• 

  Subject Areas on Research

  • (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. 
  • 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. 
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. 
  • 5-Fluorouracil in childhood solid tumors. 
  • 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. 
  • A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. 
  • A new activity of doublecortin in recognition of the phospho-FIGQY tyrosine in the cytoplasmic domain of neurofascin. 
  • A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene. 
  • A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. 
  • A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. 
  • Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. 
  • An exploratory study of environmental and medical factors potentially related to childhood cancer. 
  • Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics. 
  • Anaplastic renal cell carcinoma following neuroblastoma. 
  • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. 
  • Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. 
  • Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma. 
  • Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. 
  • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. 
  • Bilateral adrenal neuroblastoma. 
  • Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. 
  • Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. 
  • Bortezomib as a therapeutic candidate for neuroblastoma. 
  • Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations. 
  • COMT gene locus: new functional variants. 
  • Caspase-8 levels correlate with the expression of signal transducer and activator of transcription 1 in high-grade but not lower grade neuroblastoma. 
  • Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. 
  • Ciliary neurotrophic factor receptor alpha mRNA in NB41A3 neuroblastoma cells: regulation by cAMP. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Clear cell sarcoma of the gastrointestinal tract after very low-dose therapeutic radiation therapy: a case report. 
  • Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. 
  • Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. 
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. 
  • Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. 
  • Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. 
  • Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Comprehensive analysis of chromosome 1p deletions in neuroblastoma. 
  • Current concepts. Cancer in children. 
  • Cytogenetic abnormalities in two cases of neuroblastoma. 
  • Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. 
  • Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. 
  • Depletion of catalytic and regulatory subunits of protein kinase CK2 by antisense oligonucleotide treatment of neuroblastoma cells. 
  • Detailed molecular analysis of 1p36 in neuroblastoma. 
  • Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. 
  • Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. 
  • Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. 
  • Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. 
  • Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. 
  • Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. 
  • Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. 
  • Evolving biopsy techniques for the diagnosis of neuroblastoma in children. 
  • Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. 
  • Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. 
  • Expression and regulation of calcium-independent protein kinase C in NG 108-15 cell differentiation. 
  • Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. 
  • Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. 
  • GD3 expression by cultured human tumor cells of neuroectodermal origin. 
  • Ganglioglioma: a clinical study with long-term follow-up. 
  • Genetic variant rs3750625 in the 3'UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site. 
  • Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. 
  • Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. 
  • Glioneuronal tumors of the central nervous system. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. 
  • Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation. 
  • Hepatic metastasis from neuroblastoma. 
  • High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. 
  • Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Immune therapies for neuroblastoma. 
  • Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. 
  • In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. 
  • Incidence of anemia in children with solid tumors or Hodgkin disease. 
  • Induction of electrical excitability by NGF requires autocrine action of a CNTF-like factor. 
  • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. 
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. 
  • Insulin-like growth factor-I is a serum component stimulating growth of human neuroblastoma. 
  • Intractable seizures, compulsions, and coprolalia: a pediatric case study. 
  • Intraoperative radiation therapy for high-risk pediatric neuroblastoma. 
  • Involvement of gamma and beta actin isoforms in mouse neuroblastoma differentiation. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. 
  • Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. 
  • Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. 
  • Long-term results of therapy for stage C neuroblastoma. 
  • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. 
  • MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 
  • MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. 
  • Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. 
  • Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. 
  • Management of solid tumors in children. 
  • Mediastinal tumors and cysts. 
  • Medulloblastoma cell-substrate interaction in vitro. 
  • Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. 
  • Metastatic neuroblastoma presenting with binocular blindness from intracranial compression of the optic nerves. 
  • Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment. 
  • Mxi1-0, an alternatively transcribed Mxi1 isoform, is overexpressed in glioblastomas. 
  • N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. 
  • N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma. 
  • Neonatal neoplasms. 
  • Neuroblastoma grafts are noninvasively removed within mouse neocortex by selective laser activation of intracellular photolytic chromophore. 
  • Neuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus. 
  • Neurotrophins differentially regulate voltage-gated ion channels. 
  • New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. 
  • No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. 
  • No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. 
  • No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. 
  • No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. 
  • Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. 
  • Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. 
  • Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. 
  • Parc-ing p53 in the cytoplasm. 
  • Parkin is not regulated by the unfolded protein response in human neuroblastoma cells. 
  • Pediatric radiation oncology. 
  • Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. 
  • Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. 
  • Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phosphorylation of microtubule-associated proteins by protein kinase CK2 in neuritogenesis. 
  • Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1β-stimulated SK-N-SH neuronal cells. 
  • Plasma dopamine-beta-hydroxylase in the diagnosis of neuroblastoma. 
  • Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). 
  • Progress against childhood cancer: the Pediatric Oncology Group experience. 
  • Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. 
  • RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. 
  • Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. 
  • Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo. 
  • Regulation of voltage-gated ion channels by NGF and ciliary neurotrophic factor in SK-N-SH neuroblastoma cells. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Reply to J. Stenman et al. 
  • Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. 
  • Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. 
  • Role of phosphorylated MAPlB in neuritogenesis. 
  • Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. 
  • Selective neuronal cell attachment to a covalently patterned monoamine on fluorinated ethylene propylene films. 
  • Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. 
  • Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. 
  • Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. 
  • Sonographic tissue pattern in neuroblastoma. 
  • Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. 
  • Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. 
  • Subarachnoid neurolytic block under general anesthesia in a 3-year-old with neuroblastoma. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. 
  • The effect of Bacopa monnieri on gene expression levels in SH-SY5Y human neuroblastoma cells. 
  • The effect of halothane on cultured fibroblasts and neuroblastoma cells. 
  • The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. 
  • The tumor dormant state. 
  • Thoracic neural crest tumors in Beckwith-Wiedemann syndrome. 
  • Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. 
  • Two serologic markers to monitor the engraftment, growth, and treatment response of human leukemias in severe combined immunodeficient mice. 
  • Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. 
  • Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. 
  • Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. 
  • Value of surgical resection in children with high-risk neuroblastoma. 
  • Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. 
  • Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology